State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 200050, Shanghai, People's Republic of China.
Nanoscale Res Lett. 2010 Feb 14;5(4):781-5. doi: 10.1007/s11671-010-9558-5.
The P123/ACP nanocomposite with sizes less than 100 nm consisting of triblock copolymer P123 and amorphous calcium phosphate (ACP) has been prepared by using an aqueous solution containing CaCl2, (NH4)3PO4, and P123 at room temperature. The P123/ACP nanocomposite is used as the nanocarrier for hydrophobic drug ibuprofen, based on the combined advantages of both amphiphilic block copolymer and calcium phosphate delivery system. The P123/ACP nanocomposite has a much higher ibuprofen loading capacity (148 mg/g) than the single-phase calcium phosphate nanostructures. The drug release percentage of the P123/ACP nanocomposite in simulated body fluid reaches about 100% in a period of 156 h, which is much slower than that of single-phase calcium phosphate nanostructures. It is expected that the P123/ACP nanocomposite is promising for the application in the controlled delivery of hydrophobic drugs.
由三嵌段共聚物 P123 和无定形磷酸钙(ACP)组成、粒径小于 100nm 的 P123/ACP 纳米复合材料是通过在室温下使用含有 CaCl2、(NH4)3PO4 和 P123 的水溶液制备的。基于两亲嵌段共聚物和磷酸钙递送系统的综合优势,将 P123/ACP 纳米复合材料用作疏水性药物布洛芬的纳米载体。与单相磷酸钙纳米结构相比,P123/ACP 纳米复合材料具有更高的布洛芬负载能力(148mg/g)。在模拟体液中,P123/ACP 纳米复合材料的药物释放百分比在 156 小时内达到约 100%,这比单相磷酸钙纳米结构慢得多。预计 P123/ACP 纳米复合材料有望在疏水性药物的控制释放中得到应用。